

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-50 (canceled)

Claim 51 (new): A method of inhibiting B-cell growth in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds human BAFF (SEQ ID NO:1), wherein B-cell growth in the animal is inhibited.

Claim 52 (new): A method of inhibiting immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds human BAFF (SEQ ID NO:1), wherein immunoglobulin production in the animal is inhibited.

Claim 53 (new): A method of co-inhibiting B-cell growth and immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds human BAFF (SEQ ID NO:1), wherein B-cell growth and immunoglobulin production in the animal are inhibited.

Claim 54 (new): A method of inhibiting B-cell growth and maturation in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds human BAFF (SEQ ID NO:1), wherein B-cell growth and maturation in the animal are inhibited.

Claim 55 (new): A method of inhibiting B-cell growth in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds murine BAFF (SEQ ID NO:2), wherein B-cell growth in the animal is inhibited.

Claim 56 (new): A method of inhibiting immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an

anti-BAFF antibody that binds murine BAFF (SEQ ID NO:2), wherein immunoglobulin production in the animal is inhibited.

Claim 57 (new): A method of co-inhibiting B-cell growth and immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds murine BAFF (SEQ ID NO:2), wherein B-cell growth and immunoglobulin production in the animal are inhibited.

Claim 58 (new): A method of inhibiting B-cell growth and maturation in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds murine BAFF (SEQ ID NO:2), wherein B-cell growth and maturation in the animal are inhibited.

Claim 59 (new): The method according to any one of claims 51-58, wherein the anti-BAFF antibody is a monoclonal antibody.

Claim 60 (new): The methods of claim 59, wherein the antibody is recombinantly produced.

Claim 61 (new): The method as in claim 59, wherein the antibody is a chimeric antibody.

Claim 62 (new): The method as in claim 59, wherein the antibody is a humanized antibody.

Claim 63 (new): The method as in claim 59, wherein the antibody comprises human constant domains.

Claim 64 (new): The method as in claim 59, wherein the antibody is a $F(ab')_2$ fragment.